
### **Supplementary information**


Late Arc/Arg3.1 expression in the basolateral amygdala is essential for persistence of newly-acquired and reactivated contextual fear memories

Daisuke Nakayama, Yoshiko Hashikawa-Yamasaki, Yuji Ikegaya , Norio Matsuki and Hiroshi Nomura\*


## **Supplementary figures**




Supplementary Figure S1




Supplementary Figure S2




Supplementary Figure S3




Supplementary Figure S4





Supplementary figure S5



Supplementary figure S6

# **Supplementary Table**

#### **Supplementary Table 1 Statistical results**

Figure	Statistical tests and results
Figure 1A	One-way ANOVA, $F_{(4, 45)} = 6.8$ , $P = 0.00023$ ; Tukey's post hoc test, Naïve vs. 2 h,
	** $P = 0.0043$ ; 12 h, * $P = 0.012$
Figure 1B	One-way ANOVA, $F_{(4, 45)} = 8.1$ , $P = 5.1 \times 10^{-5}$ ; Tukey's post hoc test, Naïve vs. 2
	h, ** $P = 0.0044$ ; 12 h, ** $P = 0.00067$
Figure 1D	Student's <i>t</i> -test, $t_{(24)} = 7.1$ , ** $P = 2.5 \times 10^{-7}$
Figure 1E	Student's <i>t</i> -test, $t_{(14)} = 0.22$ , $P = 0.83$
	One-way ANOVA, $F_{(2, 36)} = 5.58$ , $P = 0.0077$ ; Tukey's post hoc test, IS vs. FC, *P
	=0.029
Figure 1H	One-way ANOVA, $F_{(2,12)} = 54.9$ , $P = 9.2 \times 10^{-7}$
Figure 2B	(Left) Student's <i>t</i> -test, $t_{(16)} = 0.19$ , $P = 0.85$
	(Right) Student's <i>t</i> -test, $t_{(15)} = 5.1$ , ** $P = 0.00013$
Figure 2D	(Left) Repeated measures ANOVA, $F_{(1,14)} = 0.25$ , $P = 0.63$
	(Right) Repeated measures ANOVA, $F_{(1,12)} = 8.4$ , $P = 0.013$ ; Scrambled vs.
	Antisense in test session, ** $P = 0.0086$
	Paired t-test, $t_{(6)} = 0.81$ , $P = 0.45$
Figure 3B	Repeated measures ANOVA, $F_{(3,41)} = 15.3$ , $P = 8.1 \times 10^{-7}$ ; Tukey's post-hoc test,
	Scrambled + Vehicle vs. Antisense + Vehicle in test session, ** $P = 6.6 \times 10^{-5}$ ;
	Antisense + Vehicle vs. Antisense + Ifenprodil in test session, ** $P = 7.3 \times 10^{-5}$
Figure 3D	Repeated measures ANOVA, $F_{(3,41)} = 12.0$ , $P = 9.1 \times 10^{-6}$ ; Tukey's post-hoc test,
	Scrambled + Vehicle vs. Antisense + Vehicle in test session, **P =0.0041;
	Antisense + Vehicle vs. Antisense + Ifenprodil in test session, $*P = 0.013$
Figure 3F	Repeated measures ANOVA, $F_{(3,42)} = 10.4$ , $P = 3.0 \times 10^{-5}$ ; Tukey's post-hoc test,
	Scrambled + Vehicle vs. Antisense + Vehicle in test session, $P = 5.0 \times 10^{-4}$ ;
	Antisense + Vehicle vs. Antisense + Ifenprodil in test session, P = 0.99
Figure 4B	one-way ANOVA, $F_{(2, 21)} = 7.2$ , $P = 0.0042$ ; Tukey's post hoc test, Vehicle vs
	Ifenprodil, $*P = 0.026$
Figure 4D	one-way ANOVA, $F_{(2, 21)} = 5.7$ , $P = 0.010$ ; Tukey's post hoc test, Vehicle vs
	Ifenprodil, $*P = 0.038$

### **Supplementary figure legends**

Supplementary Figure S1 Infusions of Arc antisense decrease proportion of  $Arc^+$  neurons in the BLA, related to Figure 2.

(A) Mice were infused with Arc antisense or scrambled ODNs into the BLA 7 h after memory retrieval and sacrificed 5 later (n = 4 mice). (B) Representative images of Arc immunostaining in the BLA. Scale bar, 50  $\mu$ m. (C) Infusions of Arc antisense decreased proportion of Arc+ neurons in the BLA (Student's t-test,  $t_{(4)} = 4.5$ , P = 0.011).

#### Supplementary Figure S2 Histological verification of cannula placements, related to Figure 2.

(A) Histological verification of cannula placements, related to Figure 2B left. (B) Histological verification of cannula placements, related to Figure 2B right. (C) Histological verification of cannula placements, related to Figure 2D left. (D) Histological verification of cannula placements related to Fig. 2D right. (E) Histological verification of cannula placements related to Figure 2F.

Supplementary Figure S3 NR2B-NMDARs are involved in memory destabilization that entails early and late protein expression

(A) Mice received intra-BLA injections of ifenprodil or vehicle 5 min before memory retrieval and anisomycin after memory retrieval (Vehicle + Anisomycin: n = 8 mice, Ifenprodil + Anisomycin: n = 8

8 mice). (B) (Left) The ifenprodil injections prevented memory impairment resulting from inhibiting early protein expression (repeated measures ANOVA,  $F_{(1, 14)} = 25.3$ , P = 0.00018; Vehicle + Anisomycin vs. Ifenprodil + Anisomycin in test session, \*\*P = 0.00051). (Right) Histological verification of cannula placements expression. (C) Mice received intra-BLA injections of ifenprodil or vehicle 5 min before memory retrieval and anisomycin 10 h after memory retrieval (Vehicle + Anisomycin: n = 9 mice, Ifenprodil + Anisomycin: n = 8 mice). (D) (Left) The ifenprodil injections prevented memory impairment resulting from inhibiting late protein expression (repeated measures ANOVA,  $F_{(1, 15)} = 11.8$ , P = 0.0037; Vehicle + Anisomycin vs. Ifenprodil + Anisomycin in test session, \*\*P = 0.00038). (Right) Histological verification of cannula placements.

Supplementary Figure S4 Histological verification of cannula placements, related to Figure 3.

(A) Histological verification of cannula placements, related to Fiture 3B. (B) Histological verification of cannula placements, related to Figure 3D. (C) Histological verification of cannula placements related to Figure 3F.

Supplementary Figure S5 Infusions of NR2A-preferring NMDAR antagonist disrupts memory reconsolidation

(A) Mice were infused with NVP-AAM077 into the BLA 5 min before memory retrieval. (B) (Left)

NVP-AAM077 treatment disrupted freezing behavior in the 2 d test (repeated measures ANOVA,  $F_{(1)}$ ) and  $F_{(1)} = 15.7$ , P = 0.0014; Vehicle vs. NVP-AAM077 in test session, \*\*P = 0.00045). (Right) Histological verification of cannula placements.

Supplementary Figure S6 Histological verification of cannula placements, related to Figure 4.

(A) Histological verification of cannula placements, related to Figure 4B. (B) Histological verification of cannula placements related to Figure 4D.